Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen.
暂无分享,去创建一个
S. Rosenberg | Y. Zhai | V. Bronte | N. Restifo | M. Wang | P. Chen | P. Chen | P. Chen | P. Chen
[1] S. Rosenberg,et al. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy. , 1996, Journal of immunology.
[2] S. Rosenberg,et al. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. , 1995, Journal of immunology.
[3] S. Rosenberg,et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. , 1995, Journal of immunology.
[4] H. Ertl,et al. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses , 1995, Journal of virology.
[5] Hanns Lochmüller,et al. The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. , 1995, Gene therapy.
[6] R. Crystal,et al. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis , 1994, Nature Genetics.
[7] S. Rosenberg,et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. , 1994, Journal of the National Cancer Institute.
[8] K. Sakaguchi,et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[9] A. Houghton. Cancer antigens: immune recognition of self and altered self , 1994, The Journal of experimental medicine.
[10] J. Wilson,et al. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[11] S. Rosenberg,et al. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. , 1994, Cancer research.
[12] D. Pardoll. A new look for the 1990s , 1994, Nature.
[13] E. Furth,et al. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[14] J. Wilson,et al. Adenovirus-mediated gene transfer of soluble vascular cell adhesion molecule to porcine interposition vein grafts. , 1994, Circulation.
[15] R. Henderson,et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.
[16] S. Rosenberg,et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[17] J. Changeux,et al. In vivo and in vitro analysis of electrical activity-dependent expression of muscle acetylcholine receptor genes using adenovirus. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[18] D. Pardoll. Tumour antigens. A new look for the 1990s. , 1994, Nature.
[19] M. Welsh,et al. Safety and efficacy of repetitive adenovirus–mediated transfer of CFTR cDNA to airway epithelia of primates and cotton rats , 1994, Nature Genetics.
[20] M. Kay,et al. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[21] E. Paoletti,et al. Murine cytotoxic T cell response specific for human cytomegalovirus glycoprotein B (gB) induced by adenovirus and vaccinia virus recombinants expressing gB. , 1993, The Journal of general virology.
[22] Joseph Zabner,et al. Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis , 1993, Cell.
[23] M. Bevan,et al. Alkali hydrolysis of recombinant proteins allows for the rapid identification of class I MHC-restricted CTL epitopes. , 1993, Journal of immunology.
[24] B. A. French,et al. The Advent of Adenovirus Gene Therapy for Cardiovascular Disease , 1993, Circulation.
[25] F. Graham,et al. Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. , 1993, The Journal of infectious diseases.
[26] P. Coulie,et al. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.
[27] S. Rosenberg,et al. Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain , 1993, The Journal of experimental medicine.
[28] J. Wilson,et al. Gene therapy: adenovirus vectors. , 1993, Current opinion in genetics & development.
[29] M. Perricaudet,et al. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. , 1993, The Journal of general virology.
[30] J. Yewdell,et al. Identification of human cancers deficient in antigen processing , 1993, The Journal of experimental medicine.
[31] M. Perricaudet,et al. Diversity of airway epithelial cell targets for in vivo recombinant adenovirus-mediated gene transfer. , 1993, The Journal of clinical investigation.
[32] Lynn De,et al. A BASIC computer program for analyzing endpoint assays. , 1992 .
[33] J. Mandel,et al. Adenovirus as an expression vector in muscle cells in vivo. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[34] D. E. Lynn. A BASIC computer program for analyzing endpoint assays. , 1992, BioTechniques.
[35] E. Paoletti,et al. Potential use of non-replicating vectors as recombinant vaccines. , 1992, Vaccine.
[36] A. Davis,et al. Evaluation of adenovirus type 4 and type 7 recombinant hepatitis B vaccines in dogs. , 1991, Vaccine.
[37] P. Greenberg. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.
[38] S. Rosenberg,et al. Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice. , 1990, Journal of immunology.
[39] S. Rosenberg,et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. , 1988, The New England journal of medicine.
[40] S. Rosenberg,et al. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.
[41] T. S. Jones,et al. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. , 1987, The New England journal of medicine.
[42] G. Contreras,et al. Immunization of Canadian Armed Forces personnel with live types 4 and 7 adenovirus vaccines. , 1986, Canadian journal of public health = Revue canadienne de sante publique.
[43] Michael Boshart,et al. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus , 1985, Cell.
[44] M. Brattain,et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. , 1980, Cancer research.
[45] F. H. Top. Control of adenovirus acute respiratory disease in U.S. Army trainees. , 1975, The Yale journal of biology and medicine.